Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 30, 2015 8:09 PM ET

Biotechnology

Company Overview of Immune Design Corp.

Company Overview

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. The company develops various product candidates based on its IMDZVex and GLAAS product discovery platforms. Its oncology clinical-stage product candidates include LV305, G305, and CMB305, which are in Phase-I clinical trials for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma. The company’s oncology clinical-stage product candidates also comprise G100 that is in Phase-I clinical trials for the treatment of patients with merkel cell carcinoma and sarcoma; and in pre-clinical stage f...

1616 Eastlake Avenue East

Suite 310

Seattle, WA 98102

United States

Founded in 2008

33 Employees

Phone:

206-682-0645

Fax:

206-682-0648

Key Executives for Immune Design Corp.

Chief Executive Officer, President and Director
Age: 56
Total Annual Compensation: $798.3K
Principal Financial Officer, Principal Accounting Officer and Executive Vice President of Strategy & Finance
Age: 45
Total Annual Compensation: $433.4K
Chief Medical Officer
Age: 57
Total Annual Compensation: $418.5K
Chief Development Officer
Age: 56
Total Annual Compensation: $378.7K
Compensation as of Fiscal Year 2014.

Immune Design Corp. Key Developments

Immune Design Corp. - Special Call

To discuss post-ASCO Clinical Research Update

Immune Design Corp. Announces Management Changes, Effective May 13, 2015

On May 13, 2015, Paul Rickey, Vice President, Finance and Administration of Immune Design Corp. announced his resignation effective May 31, 2015 from all of his positions with the company, including his positions as Principal Financial Officer and Principal Accounting Officer of the company, in order to pursue other endeavors. The company has hired Christopher Whitmore and appointed him as its Vice President, Finance and Administration effective May 31, 2015. Mr. Whitmore joined the company from AcelRx Pharmaceuticals Inc. Mr. Rickey will remain as a consultant to the company to assist with Mr. Whitmore's transition into his new role. Additionally, on May 13, 2015, the company appointed Stephen R. Brady as the company's Principal Financial Officer and Principal Accounting Officer effective May 31, 2015. Mr. Brady is currently serving as the company's Executive Vice President, Strategy & Finance.

Immune Design Corp. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Immune Design Corp. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $1,938,000 against $25,000 a year ago. Loss from operations was $9,406,000 against $5,513,000 a year ago. Net loss attributable to common stockholders was $9,406,000 or $0.56 per basic and diluted share against $8,223,000 or $22.25 per basic and diluted share a year ago.

Similar Private Companies By Industry

Company Name Region
ProstaGene, LLC United States
Oligonet, Inc. United States
Biomeda Corp. United States
ARx, LLC United States
Terapio Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Immune Design Corp., please visit www.immunedesign.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.